Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model

被引:0
|
作者
McManus, Emma [1 ]
机构
[1] Univ Manchester, Fac Biol Med & Hlth, Sch Hlth Sci, Hlth Org Policy & Econ,Div Populat Hlth Hlth Serv, Suite 12,Floor 7,Williamson Bldg,Oxford Rd, Manchester M13 9PL, England
关键词
LIFE-STYLE INTERVENTION; UNITED-KINGDOM; RISK; CARE; METFORMIN; ADULTS; IDENTIFICATION; STRATEGIES; MELLITUS; PEOPLE;
D O I
10.1007/s41669-024-00487-6
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background In 2016, England launched the largest nationwide diabetes mellitus prevention programme, the NHS Diabetes Prevention Programme (NHS DPP). This paper seeks to evaluate the long-term cost-effectiveness of this programme.Methods A Markov cohort state transition model was developed with a 35-year time horizon and yearly cycles to compare referral to the NHS DPP to usual care for individuals with non-diabetic hyperglycaemia. The modelled cohort of individuals mirrored the age profile of referrals received by the programme by April 2020. A health system perspective was taken, with costs in UK pound Sterling (price year 2020) and outcomes in terms of quality-adjusted life-years (QALYs). Probabilistic analysis with 10,000 Monte Carlo simulations was used. Several sensitivity analyses were conducted to explore the uncertainty surrounding the base case results, particularly varying the length of time for which the effectiveness of the programme was expected to last.Results In the base case, using only the observed effectiveness of the NHS DPP at 3 years, it was found that the programme is likely to dominate usual care, by generating on average 40.8 incremental QALYs whilst saving 135,755 pound in costs for a cohort of 1000. At a willingness to pay of 20,000 pound per QALY, 98.1% of simulations were on or under the willingness-to-pay threshold. Scaling this up to the number of referrals actually received by the NHS DPP prior to April 2020, cost savings of 71.4 pound million were estimated over the 35-year time horizon and an additional 21,472 QALYs generated. These results are robust to several sensitivity analyses.Conclusion The NHS DPP is likely to be cost-effective. Indeed, in the majority of the simulations, the NHS DPP was cost-saving and generated greater QALYs, dominating usual care. This research should serve as evidence to support the continued investment or recommissioning of diabetes prevention programmes.
引用
收藏
页码:569 / 583
页数:15
相关论文
共 50 条
  • [31] Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers
    Petelin, Lara
    Hossack, Lucinda
    Shanahan, Mary
    Mitchell, Gillian
    Liew, Danny
    James, Paul A.
    Trainer, Alison H.
    GENETICS IN MEDICINE, 2020, 22 (05) : 831 - 839
  • [32] The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK
    Elnaggar, Mohamed
    Mansinho, Joana Nunes
    Malkin, Samuel J. P.
    Whitaker, Joseph
    Hunt, Barnaby
    Glah, Divina
    Maclellan, Martina
    Ali, Samina
    DIABETES THERAPY, 2025, : 613 - 628
  • [33] The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review
    Loveman, E.
    Frampton, G. K.
    Shepherd, J.
    Picot, J.
    Cooper, K.
    Bryant, J.
    Welch, K.
    Clegg, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (02) : 1 - +
  • [34] Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis
    Choi, Sung Eun
    Brandeau, Margaret L.
    Basu, Sanjay
    BMJ OPEN, 2017, 7 (11):
  • [35] The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
    Malkin, Samuel J. P.
    Carvalho, Davide
    Costa, Catarina
    Conde, Vasco
    Hunt, Barnaby
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01)
  • [36] Long-term treatment costs and cost-effectiveness of restoration repair versus replacement
    Kanzow, Philipp
    Krois, Joachim
    Wiegand, Annette
    Schwendicke, Falk
    DENTAL MATERIALS, 2021, 37 (06) : E375 - E381
  • [37] The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model
    Kruger, J.
    Brennan, A.
    Thokala, P.
    Basarir, H.
    Jacques, R.
    Elliott, J.
    Heller, S.
    Speight, J.
    DIABETIC MEDICINE, 2013, 30 (10) : 1236 - 1244
  • [38] Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States
    Hunt, B.
    McConnachie, C. C.
    Gamble, C.
    Dang-Tan, T.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (11) : 1117 - 1120
  • [39] Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis
    Barnett, Anthony H.
    Arnoldini, Simon
    Hunt, Barnaby
    Subramanian, Gowri
    Hoxer, Christina Stentoft
    DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 1921 - 1927
  • [40] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)